Leukemia, Acute
Conditions
Brief summary
This study is designed to evaluate the safety, efficacy and Population Pharmacokinetics of Oral Posaconazole in Children with leukemia.
Detailed description
Posaconazole as a new triazole antifungal agent with broad spectrum coverage, was recommended for prophylaxis of invasive fungal disease in adults. Some studies have demonstrated the relationship between posaconazole plasma concentration and efficacy and few data have been published in children with leukemia.The purpose of this study is to describe the off-label use of posaconazole oral suspensions in children;to figure out the relationship between concentration and clinical outcomes/ adverse events;to identify factors that influence plasma concentration.
Interventions
DRUGposaconazole oral suspensions
posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
Sponsors
Guangdong Provincial People's Hospital
Zhujiang Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 14 Years
Healthy volunteers
No
Inclusion criteria
* 1、Patients age 2-14 years with acute leukemia (AML, ALL) undergoing chemotherapy and neutropenia expected to last at least 7 days. 2、Karnofsky/Lansky score of 60% or greater. 3、defined as alanine transaminase (ALT) \<3 x upper limit of normal (ULN),aspartate aminotransferase (AST) \<3 x ULN; serum bilirubin and alkaline phosphatase \<2 x ULN. 4、No other treatment and combination of triazoles antifungals and drugs like vincristine, sirolimus, cyclosporine etc. 5、Able to take oral medication or take medication via enteral feeding tube. 6、Ability to give informed consent. 7、No history of anaphylaxis attributed to the azole class of antifungal agents.
Exclusion criteria
* 1、Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction. 2、Subject is not considered eligible for this clinical research program with posaconazole. 3、Use of medications that are known to interact with posaconazole and that may lead to life-threatening side to effects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number, type and grade of adverse events of posaconazole assessed by CTCAE v4.0 | 1 year | Number, type and grade of adverse events of posaconazole oral suspensions to children with leukemia assessed by CTCAE v4.0. |
| Plasma posaconazole concentration monitoring and its pharmacokinetic | 1 year | Blood samples for determination of plasma posaconazole concentration will be collected predoses (just prior to a daily dose) on days 3, 7, 14 and 21. Anther concentration (include peak concentraton) will also be collected at least 7days after the first dose. |
Secondary
| Measure | Time frame |
|---|---|
| Serious Adverse events and drug-related adverse events monitoring | 2 years |
Countries
China
Outcome results
None listed